Payment overview · 2025
General Payments
$247.90
7 reported records · 2 companies
Healthcare provider profile · identity verified
Gamil S Kostandy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1841265949
Verified facts
What the public records show
CMS Open Payments records show Gamil S Kostandy, MD received $247.90 in general payments during 2025 across 7 reported records.
Abbott Laboratories accounted for 81.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $201.74 | 81.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.16 | 18.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.90 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $201.74 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $46.16 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 54 |
| Famotidine | Famotidine | 275 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 33 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 234 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 233 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 213 | 50 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 209 | 43 |
| Vascepa | Icosapent Ethyl | 185 | 53 |
| Metformin Hcl | Metformin Hcl | 167 | 37 |
| Montelukast Sodium | Montelukast Sodium | 162 | 30 |
| Losartan Potassium | Losartan Potassium | 144 | 28 |
| Azelastine Hcl | Azelastine Hcl | 142 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 29 |
| Omeprazole | Omeprazole | 128 | 23 |
| Diclofenac Potassium | Diclofenac Potassium | 125 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 19 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 111 | 22 |
| Creon | Lipase/Protease/Amylase | 104 | 28 |
| Clobetasol Propionate | Clobetasol Propionate | 102 | 14 |
| Lisinopril | Lisinopril | 99 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 22 |
| Naproxen | Naproxen | 81 | 15 |
| Simvastatin | Simvastatin | 81 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 80 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 71 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 66 | 16 |
| Clotrimazole | Clotrimazole | 64 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 12 |
| Januvia | Sitagliptin Phosphate | 60 | 12 |
| Ibuprofen | Ibuprofen | 58 | 15 |
| Metformin Er Gastric | Metformin Hcl | 58 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 58 | 13 |
| Ranolazine Er | Ranolazine | 58 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 14 |
| Trazodone Hcl | Trazodone Hcl | 57 | suppressed |
| Jardiance | Empagliflozin | 56 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 56 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 15 |
| Diflorasone Diacetate | Diflorasone Diacetate | 52 | suppressed |
| Ezetimibe | Ezetimibe | 50 | 11 |
| Procto-Med Hc | Hydrocortisone | 50 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Linzess | Linaclotide | 48 | 14 |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Ozempic | Semaglutide | 48 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 47 | 13 |
| Allopurinol | Allopurinol | 46 | suppressed |
| Ketoconazole | Ketoconazole | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | suppressed |
| Restasis | Cyclosporine | 45 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 45 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Celecoxib | Celecoxib | 42 | suppressed |
| Myrbetriq | Mirabegron | 42 | 14 |
| Zileuton Er | Zileuton | 42 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | suppressed |
| Lactulose | Lactulose | 38 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | 11 |
| Epinephrine | Epinephrine | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 15 |
| Clemastine Fumarate | Clemastine Fumarate | 32 | 19 |
| Atenolol | Atenolol | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Lubiprostone | Lubiprostone | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 11 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 18 | 12 |
| Xiidra | Lifitegrast | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Amcinonide | Amcinonide | 15 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ilevro | Nepafenac | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.90 · 7 records | Abbott Laboratories | CREON, FREESTYLE LIBRE 3 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error